Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Common Stock (NQ: BIAF )

1.890 +0.090 (+5.00%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,072
Open 1.770
Bid (Size) 1.720 (4)
Ask (Size) 1.890 (2)
Prev. Close 1.800
Today's Range 1.720 - 1.890
52wk Range 1.310 - 15.55
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer
From bioAffinity Technologies, Inc.
Via Business Wire

Performance

YTD
+21.15%
+21.15%
1 Month
+13.86%
+13.86%
3 Month
+18.12%
+18.12%
6 Month
-35.05%
-35.05%
1 Year
-77.23%
-77.23%

More News

Read More
bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications
From bioAffinity Technologies, Inc.
Via Business Wire
Dow Rises 80 Points; Altamira Therapeutics Shares Plunge
Via Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Edges Higher; Crude Oil Down 1%
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies to Report Third Quarter 2022 Financial Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia
From bioAffinity Technologies, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference
From bioAffinity Technologies, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.